Direct oral anticoagulants in patients with cancer

被引：2
|
作者：
Bossaer, John B. [1 ]
Covert, Kelly L. [1 ]
机构：
[1] East Tennessee State Univ, Bill Gatton Coll Pharm, Mountain Home, TN 37684 USA
来源：
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2019年 / 76卷 / 14期
关键词：
anticoagulation; atrial fibrillation; cancer; direct oral anticoagulants; supportive care; venous thromboembolism; VITAMIN-K ANTAGONIST; VENOUS THROMBOEMBOLISM; ATRIAL-FIBRILLATION; ANTITHROMBOTIC THERAPY; SUBGROUP ANALYSIS; CHEST GUIDELINE; RISK-FACTORS; WARFARIN; RIVAROXABAN; APIXABAN;
D O I：
10.1093/ajhp/zxz095
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Purpose This review summarizes the available evidence concerning direct oral anticoagulant (DOAC) use to treat venous thromboembolism (VTE) in patients with cancer as well as pertinent safety data on the use of DOACs in patients with both cancer and atrial fibrillation. Summary The introduction of DOACs into clinical practice changed the way thrombotic complications are managed and prevented in diverse patient populations, including VTE and atrial fibrillation. Low-molecular-weight heparins have been the standard of care for treating VTE in cancer patients due to superiority over vitamin K antagonists in preventing recurrent VTE. Therefore, widespread DOAC use for VTE in patients with active cancer has not been adopted. Conclusion Recent randomized clinical trials (SELECT-D, Hokusai VTE Cancer) have provided evidence that DOACs may have a role in treating VTE in cancer patients.
引用
收藏
页码：1019 / 1027
页数：9
相关论文
共 50 条
  • [1] Direct Oral Anticoagulants in Patients with Cancer
    Shah, Surbhi
    Datta, Yvonne H.
    Norby, Faye
    Alonso, Alvaro
    BLOOD, 2016, 128 (22)
  • [2] Direct Oral Anticoagulants in Cancer Patients
    Suryanarayan, Deepa
    Lee, Agnes Y. Y.
    Wu, Cynthia
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2019, 45 (06): : 638 - 647
  • [3] Direct Oral Anticoagulants in Cancer Patients
    Cosma, Edward
    Prunty, Jeremy J.
    US PHARMACIST, 2018,
  • [4] Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer
    Agnelli, Giancarlo
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08): : 781 - 783
  • [5] Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer
    Wang, Yiwei
    Wang, Maoyun
    Ni, Yuenan
    Liang, Zongan
    HEMATOLOGY, 2020, 25 (01) : 63 - 70
  • [6] Infrequent transition to direct oral anticoagulants in patients with cancer
    Nouhravesh, Nina
    Sindet-Pedersen, Caroline
    Hellfritzsch, Maja
    Al-Alak, Ali Akil
    Kuemler, Thomas
    Grove, Erik L.
    Lamberts, Morten
    DANISH MEDICAL JOURNAL, 2024, 71 (02):
  • [7] Is there a role yet for new direct oral anticoagulants in cancer patients?
    Cohen, Abigail L.
    Lim, Chung S.
    Davies, Alun H.
    PHLEBOLOGY, 2016, 31 (03) : 157 - 159
  • [8] Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation
    Davis, Margot K.
    Lim, Howard
    Lee, Agnes Y. Y.
    JACC: CARDIOONCOLOGY, 2021, 3 (03): : 425 - 427
  • [9] DIRECT ORAL ANTICOAGULANTS ARE EFFECTIVE AND SAFE IN PATIENTS WITH GYNECOLOGIC CANCER
    Shimizu, A.
    Sawada, K.
    SHiomi, M.
    Kawano, M.
    Takiuchi, T.
    Yuri, M.
    Kodama, M.
    Kobayashi, E.
    Hashimoto, K.
    Mabuchi, S.
    Ueda, Y.
    Tomomastu, T.
    Kimura, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 564 - 564
  • [10] Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients
    Sorensen, Kimberly
    Mohassel, Leila
    Kim, Jenny
    PHARMACOTHERAPY, 2017, 37 (12): : E177 - E177
12345